GSK's experimental drug to treat chronic hepatitis B infection met the main goal in two closely watched studies, the ...

The American Association for the Study of Liver Diseases and Infectious Diseases Society of America have updated guidance on ...

The clinical trial success of bepirovirsen, which will be submitted to regulatory agencies for approval, could be a boon for ...

Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even ...

MAVIRET is the first and only oral eight-week pan-genotypic treatment option approved for people with acute or chronic ...

GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...

Hepatitis C and opioid use disorder are both chronic but treatable conditions. Yet many Americans living with this deadly combination aren’t offered treatment. Imagine going to your doctor with strep ...

Hepatitis C is an infection of the liver caused by the hepatitis C virus (HCV). Experts estimate that about 2.4 million people in the United States are living with hepatitis C—but that figure could be ...

GSK plc GSK announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational ...

A new 10-year regional study reveals that adults living with both HIV and hepatitis B virus across the Asia-Pacific face ...

Hepatitis is an inflammation of the liver. It’s considered acute until it lasts six months, at which point it’s considered chronic. Complications that can develop from chronic hepatitis include a ...